Arcus Biosciences recently discontinued the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies of domvanalimab-based regimens in advanced gastric and esophageal cancers, after an interim analysis found ...
Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...
Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...
Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility. • ...
A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory ...
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences Inc (RCUS) stock reached a significant milestone, hitting a 52-week high of 26.32 USD, representing a remarkable 304% increase from its 52-week low of 6.50 USD. According to ...
The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...
Once considered a hot M&A target, Arcus Biosciences secured an upsized US$250m late on Thursday from an overnight stock sale that improves its ability to develop drugs on its own. Following an earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback